Research programme: eye disorder therapeutics - Aerie Pharmaceuticals

Drug Profile

Research programme: eye disorder therapeutics - Aerie Pharmaceuticals

Alternative Names: AR 13154; AR 13503; AR-101; AR-13165; AR-13533; AR-202

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke University Medical Center
  • Developer Aerie Pharmaceuticals; Ramot at Tel Aviv University
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Janus kinase inhibitors; Norepinephrine plasma membrane transport protein inhibitors; Platelet-derived growth factor beta receptor antagonists; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic retinopathy; Dry age-related macular degeneration; Neurological disorders; Wet age-related macular degeneration
  • No development reported Glaucoma

Most Recent Events

  • 01 Aug 2018 Aerie Pharmaceuticals and DSM Biomedical expand their collaborative research, development and license agreement for novel drug delivery technology in Eye disorders
  • 01 Aug 2018 Aerie Pharmaceuticals announces intention to submit IND application to the US FDA for AR 13503 in Wet age-related macular degeneration and Diabetic retinopathy in early 2019
  • 01 Mar 2018 Preclinical development of AR 13503 for Wet age-related macular degeneration and Diabetic retinopathy is ongoing in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top